STUDY RANDOMIZED PHASE II, COMBINATION OF ANASTROZOL (NSC 719344) MAS ZD1839 (IRESSA, NSC No. 715055, IND No. 61187) AND THE COMBINATION OF FULVESTRANT (NSC · 719276) MAS ZD1839 IN THE TREATMENT OF POSTMENOPAUS WOMEN WITH CANCER OF METASTASIC MAMA AND POSITIVE HORMONAL RECEPTORS

Not Applicable

• Conditions: -C50 Malignant neoplasm of breast; Malignant neoplasm of breast; C50

• Registration Number: PER-101-03
• Lead Sponsor: EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-02-13
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients must have estrogen and/or progesterone receptor positive histologically confirmed adenocartinoma of the breast with measurable recurrent or metastatic carcinoma of the breast.

Exclusion Criteria

not contemplated

Study & Design

• Study Type: Interventional
• Study Design: Not specified